
Loading, please wait...

Loading, please wait...

Recent biochemical research has unveiled a significant expansion in our understanding of lipid metabolism. Specifically, scientists have identified that the enzyme DHRS7 plays a critical role in DHRS7 plasmalogen biosynthesis. Plasmalogens are unique ether lipids essential for maintaining the integrity and functionality of mammalian membranes. While DHRS7B was previously known as the primary alkylglycerone phosphate reductase, this new study highlights how DHRS7 serves as a distinct but complementary functional partner.
The research utilized knockout cell models to quantify ethanolamine plasmalogens (PE[P]s) and evaluate enzymatic contributions. The investigators discovered that although DHRS7 shares sequence similarity with DHRS7B, it targets different fatty acid species. Specifically, DHRS7 contributes most significantly to the de novo synthesis of C18:1 species, followed by C16:0 and C22:4. In contrast, DHRS7B appears to support the synthesis of a broader range of all examined species. Consequently, these enzymatic differences lead to a distinct steady-state composition of lipids within the cell.
Furthermore, the study revealed a major difference in where these enzymes operate. DHRS7 resides within the endoplasmic reticulum (ER), whereas DHRS7B functions in the peroxisomes. This spatial separation suggests that the cell utilizes different compartments to fine-tune the production of specific lipid species. In vitro analysis confirmed that DHRS7 exhibits both alkylglycerone and acylglycerone phosphate reductase activities. Therefore, researchers now view DHRS7 as a novel and essential component of the cellular machinery responsible for membrane diversity.
DHRS7 specifically targets C18:1, C16:0, and C22:4 fatty acid species, while DHRS7B contributes more broadly to all plasmalogen species. Additionally, DHRS7 is located in the endoplasmic reticulum, whereas DHRS7B functions in peroxisomes.
Plasmalogens are vital components of cell membranes, particularly in the brain and heart. They act as antioxidants and are involved in signaling pathways; therefore, imbalances in their production are often linked to metabolic and neurological disorders.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.
References
Takahashi T et al. Acyl/alkyl-glycerone phosphate reductase DHRS7 is involved in the production of distinct plasmalogen species from DHRS7B. J Cell Sci. 2026 Apr 08. doi: undefined. PMID: 41948891.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study reveals DHRS7 as a novel reductase in the ER that produces specific plasmalogen species, complementing the peroxisomal activity of DHRS7B....
6 months ago

A retrospective cohort study of 7,716 ICU patients from the MIMIC-IV database demonstrates that Gradient Boosting Decision Trees significantly outperform traditional SOFA scores in predicting in-hospital mortality among patients with sepsis and diabetes, with SHAP analysis providing clinical interpretability.
Today

Occult maternal malignancy accounts for 3.82% of persistent unreportable NIPT results with genomic noise. Multiple chromosomal aberrations, notably on chromosome 18, warrant thorough oncological evaluation and whole-body MRI to ensure timely maternal diagnosis while preserving fetal care.
Today

This article reviews the forensic and clinical complexities of acute myocarditis arising on left ventricular hypertrophy in children, highlighting early diagnostic red flags and multidisciplinary postmortem autopsy protocols.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday